# BREAST & CERVICAL CANCER OVERVIEW

## **PREVENTION & EARLY DETECTION**



# CANCER SCREENING IN THE U.S.

## How are we doing?

► The *Healthy People 2020* target of 81% screening rate for breast cancer was not met in 2015, which reached 71.6% (down from 2010)

The rate for cervical cancer was 81.2% compared to the 93% target (down from 2010)

## **RECENT CANCER SCREENING BY RACE/ETHNICITY** (%)

Race/Ethnicity	Breast (50+)	Cervix	
White (NH)	72	82	
Black (NH)	75	84	
Hispanic	72	78	
Asian (NH)	66	73	
American Indian/Alaska Native	53	70	
Total	72	81	

# SCREENING RATES AND DISPARITIES

- Access to care
- Education
- ► Income
- Culture/Language
- ► Immigration/Years living in the U.S.

# **BREAST CANCER**


## **BREAST CANCER**

The most common cancer in American women, and the second deadliest

- 266,120 new cases expected this year
- More than 40,920 deaths nationwide
- Over 3.5 million Americans living with breast cancer
- ► Dates rates have fallen steadily in women >50



# **BREAST CANCER RISK FACTORS**




# BREAST CANCER SCREENING GUIDELINES FOR AVERAGE RISK WOMEN: ACS (2015) AND USPSTF (2016)

Recommendation	ACS	USPSTF
Breast Self Exam (BSE)	Not recommended	Against clinicians teaching BSE (D)
Clinical Breast Exam (CBE)	Not recommended	Insufficient evidence (I)
Mammography USPSTF GRADES	40-44: Opportunity for informed decision (Q), Annual (Q) 45-54 (S): Annual (Q)	40-49: Individual decision (C)/Biennial
A & B, C, D, I	55+ Biennial (Q), with option to continue annual screening (Q)	50-74: Biennial (B)
ACS S = Strong Q = Qualified	75+ Continue screening as long as health is good and life expectancy 10+ yrs (Q)	75+ : Insufficient evidence (I)

Table 4. Distribution of Female Population Size, 5-Year Absolute Breast Cancer Risk, and Age-Specific Breast Cancer Incidence Rates by Age

Age, y	2011 Population Size (in 1000s)ª	5-Year Absolute Breast Cancer Risk, 2009-2011, % <sup>b</sup>	Breast Cancer Incidence Rate per 100 000 Population, 2007-2011 <sup>b</sup>
0-34	72 049	0.2	5.3
35-39	9837	0.3	59.5
40-44	10576	0.6	122.5
45-49	11211	0.9	188.6
50-54	11 499	1.1	224.0
55-59	10 444	1.3	266.4
60-64	9271	1.6	346.7
65-69	6806	2.0	420.2
70-74	5204	2.1	433.8
75-79	4155	2.0	443.3
80-84	3444	1.9	420.6
≥85	3826	2.5	354.4

# DISTRIBUTION OF BREAST CANCER DEATHS BY AGE AT DIAGNOSIS, 2007-2011



# **CERVICAL CANCER**

# **CERVICAL CANCER**

- ▶ 13,240 new cases expected this year
- ► 4,170 deaths nationwide
- >300,000 pre-cancers are detected every year
- Incidence and mortality rates are stable after decades of steep declines

# **CERVICAL CANCER RISK FACTORS**

# \*\*\*HPV infection

- Women who have ever had sex
- ► Women who do not have Pap or HPV tests
- ► Women with immune problems including those who:
  - Use steroid medications on a regular basis
  - Have organ transplant
  - Are undergoing chemotherapy
  - Are infected with HIV
- ► Women who smoke

\*\*\*The main risk factor is not getting screened

# **CERVICAL SCREENING RECOMMENDATIONS, 2012**

Women <21	No screening
Women ages 21-29	Cytology alone every 3 years (liquid or conventional)
	Recommend AGAINST annual cytology
	HPV + cytology "co-testing" every 5 years (ACS: preferred)
	or Every 3 years with cytology alone (acceptable)
Women ages 30-65	**HPV testing alone every 5 years (new USPSTF recommendation)
	Recommend AGAINST more frequent screening
	Discontinue after age 65 if 3 negative cytology tests or
Women ages >65	Discontinue after age 65 if 3 negative cytology tests or 2 negative HPV tests in last 10 years with most recent test in last 5 years
Women ages >65 Post-Hysterectomy	

# **CERVICAL CANCER RECOMMENDATIONS**

- Women at any age should NOT be screened annually by any screening method
- ► HPV testing should NOT be used for screening women <30 years of age\*\*\*
- Women with a history of CIN2 or a more severe diagnosis should continue screening for at least 20 years
- These guidelines do NOT address women 1) with a history of cervical cancer, 2) who were exposed in utero to diethylstilbestrol (DES), or 3) who are immune-compromised, e.g., HIV+

# **KEY EVIDENCE SUPPORTING NEW RECOMMENDATIONS**

- Several large studies showing greater benefits and reduced harms of co-testing (HPV plus Pap) at longer screening intervals
- Modeling studies showing harms of over-screening
- Studies showing lack of benefit of screening teens
- Emerging evidence on HPV testing alone and screening after vaccination

# **SCREENING RATES, 2015**

► The rate of screening was similar among African American (86%) and white women (85%)

► However, among women of all races, screening rates are lower in

- ▶ older women
- women with no health insurance
- women with less education
- recent immigrants

# **CERVICAL CANCER RATES, US, 2011-2015, PER 100,000**

	Incidence	Mortality
All	7.4	2.3
White	7.4	2.2
African American	8.4	3.7
Asian/Pacific Islander	6.1	1.8
American Indian/AN	8.1	2.6
Hispanic/Latina	8.9	2.6

## SURVIVAL AND STAGE DISTRIBUTION

- Overall 5-year relative survival rate for cervical cancer among African American women is 56%, compared to 69% among white women
- African American women are also more likely to be diagnosed with regional- or distant-stage disease despite similar screening rates
- Racial differences in stage at diagnosis may be due to differences in the quality of screening and follow-up after abnormal results
- Lower socioeconomic status is also associated with lower screening rates, increased risk of late-stage diagnosis, and poorer survival

## **TAKE-HOME MESSAGES**

- ► Focus efforts on unscreened women
- Frequent (annual, biennial) cervical screening leads to more harms than benefits
- Screening with HPV, with or without Pap, is extremely safe and has many advantages: "preferred"
- Guidelines are based on a rigorous review and achieved broad consensus

## RESOURCES

## www.cancer.org

- Breast Cancer Screening Resources
- Cervical Cancer Screening Resources
- ► <u>HPV Vaccination Resources</u>
- ▶ 1-800-ACS-2345

# THANK YOU!



cancer.org | 1.800.227.2345

# ZUFALL HEALTH HEALTH CENTERS

Kathy Orchen, P.A., M.P.H. Quality Assurance Program Manager



The mission of the Zufall Health Center is to provide quality, affordable and culturally competent health care in partnership with our patients and the community in Northwest New Jersey.

Federally Quality Health Center delivers affordable, accessible, quality, and cost-effective primary health care to patients *regardless of their ability to pay*.









# Zufall Health Center Team-Based Care Six Sites and Mobile Van •Dover

- Hackettstown
- •Morristown
  - •Newton
- •Somerville
- •West Orange

















# Zufall Health 2018 Statistics

Served 39,000 patients in 141,000 visits

- 91% at or below 200% of Federal Poverty Level
- 49% of patients were uninsured
- 65% of patients were Latino
- 56% best served in a language other than English



## <u>Public Housing Patients – Medical, Dental</u> and Behavioral Health

- 572 Female 23 64 y.o.
- 544 Females 40 74 y.o.
- 1021 Total Females





# Zufall Health Services

Core Services – Pediatrics, Adult Medicine, Women's Health, Dental, Behavioral Health, HIV Services, Podiatry, Prenatal, Neurology, Optometry

Supportive Programs – 340B Contract Pharmacies and affordable medications, Clinical Pharmacy, Presumptive Eligibility/Enrollment, Case Management, Patient Navigation, Nutrition and SNAP-Ed

Community Outreach and Service Programs -Health Education/Screenings, Enrollment Assistance, HIV Testing, Outreach and Programs for Special Populations, School-based dental screenings, Children's oral health education, Legal services



# Cervical Cancer and Mammogram Screening Strategies

- Clinical Guidelines and Decision Support Making Tools
- Process in eCW CDSS tab
- Ongoing patient education
- Inclusion GYN in Physical Exam
- Extended hours evening and weekends
- Sites close to public housing walking distance

- Patient Reminders
- Providers Family Practice; Nurse Midwives; GYN NP – emphasis primary care
- Dedicated outreach workers
- Low cost/no cost services/contraceptive services -Family Planning Grants

# ZUFALL HEALTH CENTER POLICIES AND PROCEDURES

#### ZUFALL HEALTH

Cervical Cancer Screening and Management Guidelines Reviewed 05/09/2018 Supersedes 01/26/2017 Page 1 of 5

#### I. PURPOSE

To provide state of the art care to women who are eligible to undergo cervical cancer screening.

#### II. RESPONSIBILITY

Clinical staff at all health center sites.

#### III. POLICY

Zufall Health Center staff follows recommendations as per the USPSTF and supported by the ACS and ACOG to promote the prevention and early detection of cervical cancer.

#### IV. SUMMARY OF RECOMMENDATIONS

These recommendations apply to women who have a cervix, regardless of sexual history. These recommendations do not apply to women who have received a diagnosis of a high-grade precancerous cervical lesion or cervical cancer, women with in utero exposure to diethylstilbestrol, or women who are immunocompromised (such as those who are HIV positive). Although under consideration, final recommendations for screening with hsHPV tests only are not yet in place.

- The USPSTF recommends screening for cervical cancer in women ages 21 to 65 years with cytology (Pap smear) every 3 years or, for women ages 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years.
- The USPSTF recommends against screening for cervical cancer in women younger than age 21 years.
- The USPSTF recommends against screening for cervical cancer in women older than age 65 years who have had adequate prior screening (i.e. three consecutive negative Pap tests) and are not otherwise at high risk for cervical cancer.

#### ZUFALL HEALTH

Clinical Guidelines for Breast Cancer Screening Reviewed 05/09/2018 Supersedes 01/26/2017 Page 1 of 3

#### I. PURPOSE

To provide state of the art care to women who are eligible to undergo breast cancer screening.

#### II. RESPONSIBILITY

Clinical staff at all health center sites.

#### III. POLICY

Zufall Health Center staff follows recommendations as per the USPSTF, ACS, and ACOG to promote the prevention and early detection of breast cancer.

#### IV. SUMMARY OF RECOMMENDATIONS

These recommendations apply to asymptomatic women aged 40 years or older who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Evidence and experience have shown that early detection can lead to improved outcomes in women diagnosed with breast cancer.


#### Breast Cancer Screening Guidelines for Women - Recommended Screening Method

Population	U.S. Preventive Service Task Force 2016	American Cancer Society 2015	American College of Obstetricians and
			Gynecologists 2011
Women aged 40	The decision to start	Women aged 40 to 44	Screening with
to 49 with	screening	years should have the	mammography and
average risk	mammography in	choice to start annual	clinical breast exam
-	women prior to age 50	breast cancer screening	annually.
	years should be an	with mammograms if they	-
	individual one. Women	wish to do so. The risks of	
	who place a higher	screening as well as the	
	value on the potential	potential benefits should	
	benefit than the	be considered. Women	
	potential harms may	aged 45 to 49 years should	
	choose to begin biennial	get mammograms every	
	screening between the	year.	
1	£ 40 1 40	-	

# Zufall Health Center - QA/PI/RM Work Plan 2019

Measure	Numerator	Denominator	ZHC	Data Sources &	Action Plan	Responsible
			Goal	Methods		
UDS 6B Pap Tests	# of female patients 23-64 who had one or more Pap tests during measurement year or 2 years prior and/or	# of all female patients 23-64 who had at least one medical visit	85%	ECW/Brigit Reports with Random Chart Review and Manual Data Analysis	<ul> <li>Review updated guidelines</li> <li>Implement process to obtain release of information from women who have had paps done elsewhere</li> <li>Extract and enter data into ECW of scanned documents (esp Somerville)</li> <li>Remind women due for appointments</li> <li>Continue monitor pap results not received and obtain from LabCorp</li> <li>Continue Cervical Cancer Screening PDSA – HIV patients</li> </ul>	K. Felezzola, M. Soto, E. Hernandez, A. Colomo, J. Moore- Valverde
	# of female patients 30 - 64 over with HPV simultaneously	# of all female patients 30-64 who had at least one medical visit	85%	ECW/Brigit Reports with Random Chart Review and Manual	<ul> <li>Review updated guidelines</li> <li>Remind men and women due for 2<sup>nd</sup> vaccine</li> <li>Initiate vaccine series at nine years old</li> </ul>	K. Felezzola, M. Soto, E. Hernandez, A.
Mammogram Compliance	# of women, 50 y.o. and older receipt of mammogram every 2 years	# of women, 50 y.o. and older	70%	ECW/Brigit reports from ECW	<ul> <li>Review updated guidelines</li> <li>Implement process to obtain release of information from women who have had mammograms done elsewhere</li> <li>Extract and enter into ECW of scanned documents (esp Somerville)</li> <li>Remind women due for appointments</li> </ul>	D. Fallon, Fax Administrators, K. Orchen

# ECW Patient (CDSS Tab)



Labs DI Proce	dures	Imm/T.Inj	Referrals	Allergies	CDSS	Alerts	s Notes	(1)	Overview	DRTL	A I	listory	Order Se
territe Arthur	ta cos	SS Alerts									53	4/03/	2019
	Classic <u>a</u>	ilerts 说					Ignore (	ov Sha	All Alerts		~	💎 lified	on: 03/3
			Name		Last Dor	e Freq	Due Date	Status	orders		_		
	A1C test	CALL NEED				6 M	04/03/2019	Ĉo		0	0	<u>^</u>	
dvance Directive: NON	Alcohol	use screeni	ng			12 M	04/03/2019	(O			0		
03/31/2018) /ebEnabled: Yes	Antithre	ombic tx (IVD	or DM)			12 M	04/03/2019	Co			0		
essenger Enabled; re	Breast	cancer screer	ning			24 M	04/03/2019	Co		0	0		
ast vMsg: 02/06/201 ccount No: 137581	Cervical	cancer scree	ening			36 M	04/03/2019	l'o		0	0		
atient Balance: \$0	Colorec	tal cancer sci	reening			120 M	04/03/2019	10		0	0		
ccount Balance: \$0	Depres	sion screenii	ng			12 M	04/03/2019	Co			0		- 🔄 🔤
	HIV scre	eening				6 M	04/03/2019	lo			0	2 diab	etes
ast Appt: 03/31/2018	LDL test	ting (high ris	k)			12 M	04/03/2019	Co		0	0	is with	nout
ext Appt: 03/31/2010	Sexual	history taken	r			12 M	04/03/2019	lo			0	icatio	n, without
umped Appts: NONE	Body M	ass Index			03/31/201	8 24 M	03/31/2020	0			0	erm cu	urrent
	Smokin	g status			03/31/201	8 12 M	03/31/2019	0			0	insuli	in
New Appt					Generic Pract	ice Aler	ts						
Letters	*FIT / F	ecal Immuno	globulin Stool	Test		1 Y	04/03/2019	lo		0	0		All
Letters					Dx Practice	Alorts					_	Actio	
eClini <u>F</u> orms	Diabete	es Measures	(Hemoglobin A	1c (IH))	03/31/201		09/30/2018	10		0	0	aking	rë.
Account Inquiry 👻	guarant		consuit <u>n</u> ote		Letter Logs		Tax Lugs		🗄 Lasix 40	MGT	ablat	-	
Action +	New We	eb Enc	Flowsheets	;   P	lessenger 👻		Billing Logs		Lipitor 4	_			
ePrescription Logs	PL 9 t	o 10							Nystatin (10/27/2018)		0 UNI	T/GM C	ream: Aut

# **Patients with Non Compliant Paps**

▼ Phone

Excel spreadsheet with non compliant paps is obtained from Tableau database

Pat Last Nan Pat First Nar Dob

Patient Id

Last Visit Dat	Last Pap Da 🔻	Prior Pap Da 💌	Prior GYN Pap D 🔻	Pap Status 💌	Select 💌	Select
3/31/2018		12/31/2014	12/31/2000	Non-Compliant	All	All
3/31/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/30/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/30/2018		12/31/2014	12/31/2000	Non-Compliant	All	All
3/30/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/30/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/30/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/30/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/30/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/30/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/30/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/29/2018	1/15/2015	1/15/2015	1/15/2015	Non-Compliant	All	All
3/29/2018		12/31/2014	12/31/2000	Non-Compliant	All	All
3/29/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/29/2018		1/1/2015	1/1/2015	Non-Compliant	All	All
3/29/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/29/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/28/2018	9/4/2014	9/1/2014	9/1/2014	Non-Compliant	All	All
3/28/2018	11/13/2014	11/1/2014	11/1/2014	Non-Compliant	All	All
3/28/2018		12/31/2011	12/31/2000	Non-Compliant	All	All
3/28/2018		12/31/2012	12/31/2000	Non-Compliant	All	All
3/28/2018		12/31/2000	12/31/2000	Non-Compliant	All	All
3/27/2018	3/24/2015	3/24/2015	3/24/2015	Non-Compliant	All	All
3/27/2018	6/24/2015	6/1/2015	12/31/2013	Non-Compliant	All	All
3/27/2018		12/31/2014	12/31/2000	Non-Compliant	All	All
3/27/2018		5/6/2014	12/31/2000	Non-Compliant	All	All

### Kathy Orchen Help Desk

Pap Campaign

You forwarded this message on 11/26/2018 4:09 PM.

Cervical Cancer - Non Compliant Dec. 2017- Jan. 2018 - 357 11-26-18.xlsx 39 KB

Custom Campaigns eCW Requirements 5-30-18.pdf

Hi, Angel,

KO

It's time again for the Cervical Cancer Custom Campaign (357).

Please see attached document.

Please forward to Brian when complete and he can post the campaign. - Brian please let me know when the campaign is sent.

4

Contact me if there are questions.

Thank you.

Kathy

Kathy Orchen, P.A., M.P.H. Quality Assurance/Risk Management Coordinator Zufall Health Center 18 West Blackwell St. Dover, NJ 07801 V.

.

Patient Portal Email Message Sent to Non Compliant Women

# <section-header><section-header>

#### Dear {{patient\_first\_name}},

Our records show you are due for a PAP test. As part of your preventive health care, it is recommended that you have a Pap test regularly to screen for cervical cancer. Please call Zufall Health at {{facility\_phone}} to schedule an appointment.

Como parte de su atención médica preventiva, se recomienda que se haga una prueba de Papanicolaou con regularidad para detectar cáncer de cuello uterino. Llame a Zufall Health al {{facility\_phone}} para programar una cita.


> Regards, {{facility\_name}} {{facility\_phone}} {**facility\_ddress\_line\_1**} {{facility\_city}}, {{facility\_state}}{{facility\_zip\_code}}

# Tableau – Cervical Cancer Screening Monthly Reporting – Public Housing

## Cervical Cancer Screening

Select Site					
All					
Select Provider					
All					3 <b></b>
Select Special Pop Public Housing					•
Exclude R54					
Exclude Frailty R54					•
Year Display					
2019					•
Status					
Status Compliant					
Non-Compliant					
January 20	019	Februa	ary 2019	Mar	rch 2019
67% 245		67% 245		68% 246	
	- Co. 2010				
	33% 121		33% 121		32%
			121		118

#### Tableau – Mammogram Screening Monthly Reporting – Public Housing



#### Mammogram Screening

#### REDUCE BARRIERS TO COST SUPPORT FOR NAVIGATION



#### New Jersey Cancer Education and Early Detection (NJCEED)

The New Jersey Cancer Education and Early Detection (NJCEED) Program provides comprehensive outreach, education and screening services for breast, cervical, colorectal and prostate cancers.

The services provided by NJCEED include:

- •Education
- •Outreach
- •Screening
- •Case Management
- •Tracking
- •Follow-up
- •Facilitation into Treatment

Persons eligible for these services must be at or below 250% of the Federal Poverty Level and be uninsured or underinsured.

Program services are provided through 21 contracted Lead Agencies; each county in NJ has at least one Lead Agency.

#### COLORECTAL CANCER AWARENESS

Many women mistakenly believe that colorectal cancer (cancer of the colon and rectum) is a "man's disease." But the fact is that colorectal cancer (CRC) strikes women nearly as often as men. If colorectal cancer is d early enough, the patient has a

Colorectal cancer can develop from Polyps (grape-like growths on the inner lining of the colon and rectum). All women aged 50 and older are at risk for developing CRC because that is the age at which polyps usually begin to form.

Regular screening is crucial since patients do not typically have symptoms in early stages for CRC. when the cancer is more curable.

Screening tests can find polyps, so they can be removed before they turn into cancer.

Cancer is the second leading cause of death for women in the United States. Too many of our loved ones are dying of cancers that could have been prevented or treated successfully, if detected earlier.

Early detection - finding a cancer before it spreads - gives you the best chance of survival.

Treatment for breast, cervical and colorectal cancer is more effective when detected in its early stages.


> NEW JERSEY CANCER EDUCATION & **EARLY DETECTION**

 Provides early detection screenings for breast, cervical and colorectal cancer. Provides outreach and education Provides case management Provides follow-up to patients diagnosed through the NJCEED

For more information and to finc out if you are eligible for a Free cancer screening. Make the Call!! 1-800-328-3838

**J**Health

C2076



Early Detection is

For more information and to find out if you are eligible for Free cancer screenings,

Sussex County Office of Public Health Nursing NJCEED Program 973-579-0570 x 1246 or 1248

#### CÁNCER COLORRECTAL (CANCER DEL COLON Y DEL RECTO)

Hay muchas mujeres que equivocadamente creen que el cáncer colorrectal (cáncer del colon y del recto) es una "enfermedad de hombres". Sin embargo, el cáncer colorrectal se desarrolla en las mujeres casi tanto como en los hombres. Si se descubre el cáncer olorrectal en sus primeras etapas, el

probabilidad de sobrevivir.

El cáncer colorrectal surge de pólipos (bultos con forma de uva en el revestimiento interno del colon y recto). Todas las mujeres de 50 años o más tienen riesgo de desarrollar cáncer colorrectal por ser la edad en que normalmente se forman los pólipos.

Hacerse exámenes regularmente es crucial, ya que típicamente no hay sintomas en las etapas iniciales del cáncer colorrectal, cuando el cáncer es más curable. Los exámenes pueden encontrar pólipos que se pueden remover antes que desarrollen cáncer.

El cáncer es la segunda causa mayor de muerte en las mujeres en los Estados Unidos. Muchos de nuestros seres queridos mueren de cáncer. Estos casos se hubieran podido prevenir o tratar efectivamente si se hubieran detectado a tiempo. La detección a tiempo- es encontrar el cáncer antes que se extienda - le da a usted mejor posibilidad de supervivencia. El tratamiento para el cáncer de seno,

cervical y colorrectal es más eficaz cuando se detecta en sus etapas iniciales.

#### EL PROGRAMA DE EDUCACIÓN Y DETECCIÓN TEMPRANA DE CÁNCER EN NEW JERSEY (NJCEED, por sus siglas en inglés)

- Proporciona pruebas de detección temprana de cáncer de; seno, cervical y colorrectal.
- Concientiza la comunidad sobre la prevención, detección y tratamiento.
- Ofrece manejo de casos Provee seguimiento a pacientes
- diagnosticados por medio del programa de NJCEED.



C2071







#### ¡Hágase las pruebas hoy!

Para mayor información y enterarse si usted es elegible para hacerse GRATIS las pruebas de detección de cáncer,

> Oficina de Enfermeria de Salud Publica del Condado de Sussex Programa NJCEED 973-579-0570 X 1246 or 1248

# Cervical Cancer and Mammogram Screening Strategies

- Clinical Guidelines and Decision Support Making Tools
- Process in eCW CDSS tab
- Ongoing patient education
- Inclusion GYN in Physical Exam
- Extended hours evening and weekends
- Sites close to public housing walking distance

- Patient Reminders
- Providers Family Practice; Nurse Midwives; GYN NP – emphasis primary care
- Dedicated outreach workers
- Low cost/no cost services/contraceptive services -Family Planning Grants



<u>Kathy Orchen, PA, MPH</u> <u>korchen@zufallhealth.org</u>

# San Ysidro Health

### Women's Health Cancer Detection Program

*Alejandrina Arevalo Director of Patient Engagement* 






The mission of San Ysidro Health is to improve the health and well-being of the communities we serve with access for all.



# Clinic Locations and Services



## At A Glance

Our Patient Care consists of clinical **treatment** for patients:

- Medical
- Behavioral Health
- Dental
- Specialty (HIV, Chiropractic Care, Optometry, Cardiology, Ophthalmology, Podiatry)

Our Patient Experience consists of clinical **support** for patients:

- Case Management
- Outreach
- Nutrition
- Health Education
- Family Support Programs (WIC)
- Research

Our Patient Profile Is:

- Nearly 97,000 patients, generating 453,348 annual visits
- 91.92% of patients live at or below 200% of the Federal Poverty Level
- 40% are children (ages of 0-19 years)
- 22.20% are seniors (ages 55+ years)





Cancer Detection Program (Every Woman Counts)

Our mission is to reduce mortality from breast and cervical cancer among low-income women.

For a woman to be eligible for EWC, her PCP must certify that she is uninsured or underinsured, based on the woman's selfreport.



### **Patient Engagement Strategies**



- Mammogram events per site
  - Mobile mammogram unit
  - After hours PAP events
- Incentives
  - Hygiene kit
  - Gift card
- Outreach
  - At internal health fairs
  - By phone or mail.



### **2018 Breast Cancer Screening**

- Total mammograms completed:
- Abnormal results:
- Breast Cancer:

8785 2726 31



### 2019 Breast Cancer Screening (1<sup>st</sup> Quarter)

	EWC	Non-EWC
# of Patients	446	3,030
# of Screening Mammograms	305	2,175
# of Diagnostic Mammogram, Biopsy, Ultrasound	145	636
# of Breast Cancer Diagnosis	5	10



### **2018 Cervical Cancer Screening**

- Total PAPs completed:
- Abnormal results:
- Cervical Cancer:

16014 1824 8



## 2019 Cervical Cancer Screening (1<sup>st</sup> Quarter)


	EWC	Non-EWC
# of Patients	223	1,864
# of PAPs	154	1,062
# of Abnormal PAPs	14	182
# of Cervical Cancer	0	4



## Challenges

- Patients lost to follow up
  - Patient that were initially contacted and unable to reach subsequently
  - Patients unable to reach despite multiple calls and/or letters

- Non-compliant patients
  - No show for mammogram and/or PAP appointment



No follow up after results

#### **Best Practices**



- Team Based Approach
  - CDP Case Manager
  - Clinic Manager
  - Patient Navigator
  - Medical Assistant
  - Referral Specialist
  - Provider
- Patient Education and CDP Promotion
  - Events
  - Flyers
  - At PCP visit
  - Phone
  - Mail





